Preventing obesity-related HFpEF
Official title: OBESE-HFpEF: Prevalence and Mediators of Heart Failure (Preserved Ejection Fraction) in the Dutch Obesity Clinic South - Towards Preventing Obesity Related HFpEF''
Run by Zuyderland Medisch Centrum · NCT07539766 · Data updated 2026-11-12
We will follow about 250 adults with obesity who are having metabolic bariatric surgery to see if weight loss prevents or reverses early HFpEF.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 35 Years and up |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Zuyderland Medisch Centrum Academic / other |
| Locations | 1 site (Heerlen, Limburg) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | May 1, 2028 |
| Study ends | January 1, 2029 |
| Registry record updated | April 20, 2026 |
| Trial ID | NCT07539766 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 35 or older with obesity (BMI ≥40 kg/m2 or BMI ≥35 kg/m2 with an obesity-related comorbidity) who are eligible for metabolic bariatric surgery, can undergo the study tests, and are proficient in Dutch.
✕Probably not a fit
Patients with a history of reduced LVEF, severe valvular or congenital heart disease, prior bariatric surgery, BMI >60 kg/m2, inability to safely undergo surgery or study tests, or who cannot give informed consent or speak Dutch are unlikely to benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational longitudinal cohort will enroll about 250 adults with obesity who are eligible for metabolic bariatric surgery and perform extensive baseline phenotyping including echocardiography, blood tests, and adipose tissue sampling. Participants will receive standard multidisciplinary care with bariatric surgery and lifestyle support, and will return for repeated cardiac and functional assessments at 1 and 2 years. The study aims to determine how common HFpEF and pre-HFpEF are in patients seeking surgery and to track changes in cardiac function, biomarkers, quality of life, and 6-minute walk distance after weight loss. Data will be used to examine reclassification between HFpEF categories and identify pathophysiologic mediators linked to improvement or persistence of disease.
Why it matters
Potential benefit: If successful, the findings could show that substantial weight loss after bariatric surgery prevents or reverses early HFpEF, improving symptoms and long-term outcomes.
How similar studies have gone: Previous observational studies and surgical cohorts have reported cardiac and symptomatic improvements after bariatric surgery, but prospective data specifically documenting reversal or reclassification of HFpEF are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 35 years * Eligible for surgical treatment for obesity, according to the Dutch guideline, i.e. a BMI ≥ 40 kg/m2 or a BMI ≥ 35 kg/m2 with one or more comorbidities associated with obesity. (23) Exclusion Criteria: * Inability to provide informed consent. * A BMI \>60 kg/m2 * Inability of undergoing metabolic bariatric surgery safely. * Inability to undergo the study measurement/tests. * Not proficient in the Dutch language * A medical history of a reduced LVEF at any time, history of severe cardiac valve defects or severe congenital cardiac defects. * A medical history of previous metabolic bariatric surgery.
Where it's running
-
Zuyderland Medisch Centrum Heerlen
Heerlen, Limburg, Netherlands Recruiting
Study contacts
- Principal investigator: Sandra van Wijk, Dr. — Zuyderland Medical Center
- Study coordinator: Lukas Peeters, Master of Science in Medicine
- Email: luka.peeters@zuyderland.nl
- Phone: +32479092470
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Selenium supplementation for people with heart failure
This trial will test whether taking a daily selenium supplement helps people with heart failure avoid hospitalization and reduce the risk of death.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
-
Tailored digital support to cut sedentary time in long-term cardiac rehab
In adults in a long-term cardiac rehabilitation program, this study tests whether a personalized behavioural program with digital tools can reduce daily sitting time.
-
Weight-loss drugs tirzepatide vs. semaglutide in adults with obesity
This trial tests whether 12 weeks of tirzepatide or semaglutide have different effects on energy balance in adults with obesity but no diabetes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.